CD19 CAR T-cell outcomes in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) vary significantly based on the disease site. While CAR T-cell therapies effectively eliminate bone marrow leukemia, clinicians often question their performance in extramedullary and central nervous system (CNS) sites. Furthermore, a recent multi-site retrospective review provides critical insights into survival and relapse rates across these diverse disease compartments.

Survival Rates and Efficacy in Various Cohorts

The study analyzed 308 patients to evaluate survival metrics across isolated bone marrow (iBM), extramedullary disease (EMD), and CNS involvement. Consequently, researchers found that the 24-month overall survival (OS) was 71.5% for the iBM cohort. In contrast, the OS for the EMD and CNS cohorts reached 66.7% and 57.0%, respectively. Similarly, the 24-month event-free survival (EFS) showed a significant drop for patients with CNS disease at only 35.2%, compared to 51.8% for iBM.

Clinical Impact of CD19 CAR T-cell Outcomes

Notably, isolated disease presentations yielded more favorable results. All five patients in the isolated EMD cohort achieved complete remission without subsequent relapse. Additionally, 80% of patients with isolated CNS disease cleared the leukemia from the nervous system. However, 37.5% of those patients later experienced a relapse. This suggests that while initial clearance is achievable, maintaining long-term remission in CNS sites remains a difficult clinical hurdle.

Disease Burden as a Prognostic Factor

Specifically, the total disease burden at the time of infusion acts as a primary driver of outcomes. High disease burden (HD) in concurrent EMD or CNS disease led to inferior survival compared to low disease burden (LD). For instance, patients with EMD-HD had an OS of 41.7%, while those with EMD-LD achieved 100%. Moreover, the CNS-HD group showed an OS of only 33.3%, which significantly pales in comparison to the 92.3% observed in the CNS-LD group.

Frequently Asked Questions

Does CNS involvement negatively affect CD19 CAR T-cell outcomes?

Yes, patients with active CNS disease typically experience lower overall and event-free survival rates compared to those with isolated bone marrow disease. Although initial CNS clearance is common, the risk of systemic or local relapse is higher in this specific cohort.

How does disease burden influence survival in extramedullary B-ALL?

Disease burden is a critical prognostic factor. Patients with low disease burden in extramedullary or CNS sites have significantly better survival outcomes, often reaching 90-100%, compared to those with a high disease burden who show much lower survival rates.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Rankin AW et al. CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review. Blood Adv. 2026 Feb 17. doi: undefined. PMID: 41701972.

Holland EM, et al. Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood Adv. 2022.

Leahy AB, et al. CD19-targeted CAR T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021.